While lung cancer is the most common fatal cancer in most populations of the world, the mechanismsby which tobacco smoke or other carcinogens cause lung cancer and the genetic factors that might enhancesusceptibility are only partly understood. Several lines of evidence suggest, however, that inflammation maybe a potential key pathway in lung carcinogenesis. Some of the most novel and promising findings from theInitial Vanderbilt Lung SPORE (P50 CA090949) were the demonstration of the potential utility of urinarymetabolites of prostaglandin E2 (PGE2), a key mediator of the COX-2 pathway, as an inflammationbiomarker and the detection of polymorphisms in the prostacyclin synthase (PTGIS) gene in assessingindividual risk for lung cancer. We propose in this application to follow up these promising clues in aprospective study by examining the relations of the urinary PGE2 metabolite PGE-M and the prostacyclin(PGI2) metabolite PGI-M with the risk of lung cancer. Over the past ten years, we have establishedtremendous resources in two NCI-funded cohort studies, the US Southern Community Cohort Study (SCCS)(R01 CA092447) and the Chinese Shanghai Women's Health Study (SWHS) (R01 CA70867). In this application, we will take advantage of these valuable resources and propose a large nestedcase-control study to investigate: 1) the association of lung cancer risk and the urinary prostaglandin E2metabolite (PGE-M) and urinary prostacyclin metabolite (PGI-M); and 2) the association of lung cancer riskwith genetic polymorphisms of the genes involved in prostaglandin synthesis (PTGS2, PTGS1, PTGES, andPTGIS) and metabolism (15-PGDH). We will also investigate the association of lung cancer risk with plasmaC-reactive protein (CRP), a sensitive marker of systemic inflammation, and the urinary leukotriences E4.Only a few cohort studies have collected both blood and urine samples at baseline to comprehensivelymeasure relevant biomarkers. Therefore, the SCCS and SWHS, with their wealth of survey data andbiospecimens, represent a unique opportunity to prospectively investigate the hypotheses proposed in thisapplication. The proposed study is highly innovative and extremely cost-efficient. The study has greatpotentials to generate valuable biomarker information useful for identifying persons at high risk andamenable for screening for the detection of these cancers at an early, more curable stage.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA090949-06A1
Application #
7313910
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Project Start
2007-04-01
Project End
2012-03-31
Budget Start
2007-04-01
Budget End
2008-03-31
Support Year
6
Fiscal Year
2007
Total Cost
$320,512
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Codreanu, Simona G; Hoeksema, Megan D; Slebos, Robbert J C et al. (2017) Identification of Proteomic Features To Distinguish Benign Pulmonary Nodules from Lung Adenocarcinoma. J Proteome Res 16:3266-3276
Udyavar, Akshata R; Wooten, David J; Hoeksema, Megan et al. (2017) Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity. Cancer Res 77:1063-1074
Uzhachenko, Roman; Shanker, Anil; Dupont, Geneviève (2016) Computational properties of mitochondria in T cell activation and fate. Open Biol 6:
Pulliam, Stephanie R; Pellom Jr, Samuel T; Shanker, Anil et al. (2016) Butyrate regulates the expression of inflammatory and chemotactic cytokines in human acute leukemic cells during apoptosis. Cytokine 84:74-87
Edmonds, Mick D; Boyd, Kelli L; Moyo, Tamara et al. (2016) MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer. J Clin Invest 126:349-64
Boutaud, Olivier; Sosa, I Romina; Amin, Taneem et al. (2016) Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis. Cancer Prev Res (Phila) 9:855-865
Pulliam, Stephanie R; Uzhachenko, Roman V; Adunyah, Samuel E et al. (2016) Common gamma chain cytokines in combinatorial immune strategies against cancer. Immunol Lett 169:61-72
Whang, Y M; Park, S I; Trenary, I A et al. (2016) LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells. Oncogene 35:856-66
Hassanein, Mohamed; Hight, Matthew R; Buck, Jason R et al. (2016) Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer. Mol Imaging Biol 18:18-23
Qian, Jun; Hassanein, Mohamed; Hoeksema, Megan D et al. (2015) The RNA binding protein FXR1 is a new driver in the 3q26-29 amplicon and predicts poor prognosis in human cancers. Proc Natl Acad Sci U S A 112:3469-74

Showing the most recent 10 out of 217 publications